BioCryst Pharma (BCRX) Tops Q2 EPS by 1c; Sees Increase in Net Operating Cash
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.99 +0.45%
EPS Growth %: -13.3%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -13.3%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q2 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $5.44 million.
Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Based upon current trends and assumptions, as well as the Company’s planned operations, BioCryst expects net operating cash use to be in the range of $37 to $43 million, reflecting an increase of $5 million from previous projections, and its total operating expenses to be in the range of $57 to $69 million, unchanged from previous projections.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Morgan Stanley Downgrades Melco Resorts (MLCO) to Equalweight
- Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
